Cingulate Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cingulate Inc. (CING) on January 29, 2024, covering events occurring on January 25, 2024. The Company is a Delaware corporation with its principal executive offices in Kansas City, KS. The filing details the conversion of outstanding debt into equity and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Transactions
- Debt Conversion: The Company converted the remaining principal of $3,000,000 plus accrued interest totaling $3,287,500 under an Amended and Restated Promissory Note into pre-funded warrants.
- Equity Issuance: The conversion resulted in the issuance of 687,043 pre-funded warrants to purchase common stock at a conversion price of $4.785 per warrant.
- Exercise Terms: The new warrants have an exercise price of $0.0001 per share and no expiration date, subject to beneficial ownership limitations (19.99%).
- Debt Status: Following this transaction, the Amended and Restated Promissory Note was paid in full, and the Company has no further obligations under it.
- Stock Price: The closing price of Common Stock on Nasdaq on January 24, 2024, was $4.35 per share.
Material Changes and Management Commentary
The primary material change is the elimination of $3.2875 million in debt obligations through equity conversion, which improves the Company's balance sheet by removing interest-bearing liabilities. This transaction follows a similar conversion of $5.8125 million in September 2023. The filing notes that Peter J. Werth, a Board member, manages the lender (Werth Family Investment Associates LLC), indicating a related-party transaction.
Executive Appointment and Compensation
On January 25, 2024, Jennifer L. Callahan was appointed Senior Vice President and Chief Financial Officer, effective immediately. She will serve as the Principal Financial and Accounting Officer.
- Compensation: Her base salary is set at $350,000 annually but is reduced by 40% to $210,000 due to cost-containment measures.
- Deferred Compensation: The Company will pay the aggregate amount of the salary reduction plus 20% of that reduction three months after the filing of the New Drug Application for CTx-1301.
- Bonus: She is eligible for an annual bonus with a target of 25% of her base salary.
- Severance: In the event of termination without cause or for Good Reason, she is entitled to one times her base salary and annual target bonus, plus accelerated vesting of options.
Risks and Contingencies
The pre-funded warrants were issued pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) and have not been registered. The Company faces potential dilution upon the exercise of these warrants, though the exercise price is nominal ($0.0001). The Company is also subject to the standard risks associated with emerging growth companies and the development of its pharmaceutical candidates.
Investor Verification Checklist
- Verify the total number of outstanding shares and the potential dilution impact of the 687,043 new pre-funded warrants.
- Confirm the status of the New Drug Application for CTx-1301, as this triggers the deferred salary payment to the new CFO.
- Review the full text of the Note Conversion Agreement (Exhibit 10.1) for any covenants or conditions not summarized here.
- Monitor the Company's cash burn rate and liquidity position following the debt conversion to assess runway for operations.